Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by SizzlinSteakson Apr 17, 2018 10:45pm
155 Views
Post# 27902237

RE:This is how institutions short shares with warrants

RE:This is how institutions short shares with warrantsThat is one senerio, but there are other possibilities. It sounds like you are implying that the same institution that holds the warrants is shorting the stock (very possible). However, there may be a different institution or entity, that is well aware of the fact Echelon is dumping to exercise debentrues so they are shorting to bring it down, knowing very well Echilon will play right into their hands and sell them cheap shares. Make sense?

The thing I don't understand is why Echelon whould wait until the last week to sell, when they've had 4 months to do it at much higher prices. So dumb. What a bunch of knuckle heads. Oh well, one's misfortune is another's opportunity. 

mingzhu wrote: suppose they have 1 m share and 1 m warrants. They short shares of Kaly at 0.20, SP goes to 0.13, they got 0.07 profit. It goes to 0.10, profit is 0.10,but they lost 0.03 of warrants It is still 0.07 in the end. If they are wriong. SP goes up to 0.30, thye lost 0.10 but they can exercise warrants at 0.13, get back 0.17. They still have 0.07 profit. No matter what happen to SP, they always win..That is why they are so confident to short shares with warrants backup.  


Bullboard Posts